Research Article
Meta-Analysis of Brain Volumetric Abnormalities in Patients with Remitted Major Depressive Disorder
Table 2
Sample characteristics and MRI procedures of included longitudinal studies.
| | Study (publication year) | Number (female) | Mean age (y) | Age of onset | Follow-up period | Illness duration (months) | No. of episodes | Mean depression severity | Therapy | Comorbidity with anxiety (rate%) | MRI procedures | | Pretreat | Posttreat | Field strength | Voxel size (mm3) | MRI scanner |
| | Arnone et al. (2013) [23] | 23 (20) | 36.3 | 22.0 | 8 weeks | NA | 3.3 | 27.2 (MADRS) | 3.9 (MADRS) | Citalopram | 0/23 (0%) | 1.5 T | | Philips Intera | | Cano et al. (2017) [31] | 12 (6) | 59.17 | 40.58 | 5 weeks | 61.75 weeks | 4.08 | 31.25 (HDRS-17) | 2.92 (HDRS-17) | MECT+antidepressant+antipsychotics | 3/12 (25%) | NA | | Philips Achieva 3.0 | | Fang et al. (2015) [24] | 20 (8) | 59.2 | 56.1 | 8 weeks | | 2.1 | 26.6 (HDRS-17) | 6.4 (HDRS-17) | Antidepressants | NA | 1.5 T | | Siemens | | Kong et al. (2014) [25] | 24 (14) | 36.12 | NA | 8 weeks | 4.12 | NA | 21.64 | 3.4 (HDRS) | Fluoxetine | NA | 1.5 T | | GE Signa | | Lemke et al. (2022) [26] | 42 (24) | 38.79 | NA | | 14.06 | NA | 4.36 (HDRS-17) | 2.55 (HDRS-17) | Antidepressants | NA | 3.0 T | NA | NA | | Wang et al. (2017) [30] | 23 (12) | 38.74 | 33.90 | ≤3 weeks | 70.35 | NA | 22.22 (HDRS-17) | 3.83 (HDRS-17) | MECT+antidepressant+antipsychotics | NA | 3.0 T | | Signa HDxt, GE Healthcare, Buckinghamshire | | Zaremba et al. (2018) [32] | 23 (13) | 32.5 | NA | weeks | 15.3 weeks | 2.7 | 22.4 (HDRS-17) | 4.3 (HDRS-17) | Antidepressant+antipsychotic+mood stabilizers | NA | 3.0 T | | Philips Medical Systems |
|
|
BDI = Beck Depression Inventory; HCs = healthy controls; HDRS-17 = 17-item Hamilton Depression Rating Scale; m = months; MADRS = Montgomery and Åsberg Depression Rating Scale; MRI = magnetic resonance imaging.
|
